Characteristics of and risk factors for pneumonia in patients with hematological malignancies developing fever after autologous blood stem cell transplantation. Puig, N., Rubia, J. D. L., Jarque, I., Salavert, M., Moscardó, F., Sanz, J., Lorenzo, I., Montesinos, P., Martín, G., Martínez, J., Sanz, G., Blanes, M., & Sanz, M. Leukemia & Lymphoma, 48(12):2367–2374, January, 2007. Publisher: Taylor & Francis _eprint: https://doi.org/10.1080/10428190701694178
Characteristics of and risk factors for pneumonia in patients with hematological malignancies developing fever after autologous blood stem cell transplantation [link]Paper  doi  abstract   bibtex   
We analyzed the incidence, etiology, risk factors and outcomes of 49 episodes of pneumonia that developed in 326 adult patients undergoing autologous stem-cell transplantation (ASCT) from January 1990 to December 2005. The median time for the onset of pneumonia after transplantation was 11 days (range 0 – 148). Empirical antibiotic therapy in patients with pneumonia consisted of piperacillin – tazobactam (20 cases, 49%), third-generation cephalosporin (11 cases, 27%) and carbapenem (8 cases, 19%). Multivariate analysis showed that a higher risk of pneumonia could be predicted for patients with myeloma (P = 0.006) and for patients with an absolute neutrophil count \textless0.5 × 109/L \textgreater7 days (P = 0.008). Cumulative incidence of transplant-related mortality at 6 months was 51% versus 8% for patients with or without pneumonia, respectively (P = 0.001). Pneumonia after ASCT is a severe complication more commonly observed in patients with myeloma and with prolonged duration of neutropenia.
@article{puig_characteristics_2007,
	title = {Characteristics of and risk factors for pneumonia in patients with hematological malignancies developing fever after autologous blood stem cell transplantation},
	volume = {48},
	issn = {1042-8194},
	url = {https://doi.org/10.1080/10428190701694178},
	doi = {10.1080/10428190701694178},
	abstract = {We analyzed the incidence, etiology, risk factors and outcomes of 49 episodes of pneumonia that developed in 326 adult patients undergoing autologous stem-cell transplantation (ASCT) from January 1990 to December 2005. The median time for the onset of pneumonia after transplantation was 11 days (range 0 – 148). Empirical antibiotic therapy in patients with pneumonia consisted of piperacillin – tazobactam (20 cases, 49\%), third-generation cephalosporin (11 cases, 27\%) and carbapenem (8 cases, 19\%). Multivariate analysis showed that a higher risk of pneumonia could be predicted for patients with myeloma (P = 0.006) and for patients with an absolute neutrophil count {\textless}0.5 × 109/L {\textgreater}7 days (P = 0.008). Cumulative incidence of transplant-related mortality at 6 months was 51\% versus 8\% for patients with or without pneumonia, respectively (P = 0.001). Pneumonia after ASCT is a severe complication more commonly observed in patients with myeloma and with prolonged duration of neutropenia.},
	number = {12},
	urldate = {2024-10-08},
	journal = {Leukemia \& Lymphoma},
	author = {Puig, Noemí and Rubia, Javier De La and Jarque, Isidro and Salavert, Miguel and Moscardó, Federico and Sanz, Jaime and Lorenzo, Ignacio and Montesinos, Pau and Martín, Guillermo and Martínez, Jesús and Sanz, Guillermo and Blanes, Margarita and Sanz, Miguel},
	month = jan,
	year = {2007},
	pmid = {18067012},
	note = {Publisher: Taylor \& Francis
\_eprint: https://doi.org/10.1080/10428190701694178},
	keywords = {Pneumonia, autologous stem cell transplantation, infectious complications, mortality, pneu},
	pages = {2367--2374},
}

Downloads: 0